JP Morgan Chase
FTH

JP Morgan Chase’s Faeth Therapeutics FTH Stock Holding History

JP Morgan Chase’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$804 Hold
32
– – ﹤0.01% 7148
2025
Q4 		$341 Hold
32
– – ﹤0.01% 7114
2025
Q3 		$302 Hold
32
– – ﹤0.01% 7087
2025
Q2 		$275 Sell
32
-3
-9% -$22 ﹤0.01% 6751
2025
Q1 		$276 Hold
35
– – ﹤0.01% 6760
2024
Q4 		$345 Hold
35
– – ﹤0.01% 6843
2024
Q3 		$422 Sell
35
-2
-5% -$24 ﹤0.01% 6820
2024
Q2 		$464 Buy
37
+4
+12% +$83 ﹤0.01% 6695
2024
Q1 		$701 Hold
33
– – ﹤0.01% 6676
2023
Q4 		$462 Hold
33
– – ﹤0.01% 6939
2023
Q3 		$501 Hold
33
– – ﹤0.01% 6729
2023
Q2 		$762 Hold
33
– – ﹤0.01% 6492
2023
Q1 		$1K Hold
33
– – ﹤0.01% 6551
2022
Q4 		$1K Sell
33
-53
-62% -$1.56K ﹤0.01% 6443
2022
Q3 		$3K Buy
86
+21
+32% +$825 ﹤0.01% 6196
2022
Q2 		$3K Sell
65
-7,753
-99% -$291K ﹤0.01% 6249
2022
Q1 		$361K Sell
7,818
-171
-2% -$13.6K ﹤0.01% 4887
2021
Q4 		$926K Sell
7,989
-478
-6% -$71.4K ﹤0.01% 4450
2021
Q3 		$1.78M Sell
8,467
-487
-5% -$88.7K ﹤0.01% 3874
2021
Q2 		$1.75M Buy
8,954
+1,172
+15% +$289K ﹤0.01% 3890
2021
Q1 		$2.26M Buy
+7,782
New +$2.6M ﹤0.01% 3628

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

JP Morgan Chase's FTH Position: Q1 2026 in Review

JP Morgan Chase held its Faeth Therapeutics (FTH) position steady in Q1 2026 at 32 shares worth $804. The position accounts for ﹤0.01% of the portfolio, ranked #7148.

JP Morgan Chase first reported a position in FTH in Q1 2021 and has held it in 21 quarters since. The position peaked at $2.26M in Q1 2021. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • JP Morgan Chase held 32 shares of Faeth Therapeutics worth $804 as of Q1 2026.
  • JP Morgan Chase left its Faeth Therapeutics share count unchanged in Q1 2026.
  • Faeth Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7148 holding.
  • JP Morgan Chase first reported a position in Faeth Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's Faeth Therapeutics position peaked at $2.26M in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.